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A B S T R A C T   
Introduction/background & aims: Early life is marked by distinct and rapidly evolving immunity and increased 
susceptibility to infection. The vulnerability of the newborn reflects development of a complex immune system in 
the face of rapidly changing demands during the transition to extra-uterine life. Cytokines and chemokines 
contribute to this dynamic immune signaling network and can be altered by many factors, such as infection. 
Newborns undergo dynamic changes important to health and disease, yet there is limited information regarding 
human neonatal plasma cytokine and chemokine concentrations over the first week of life. The few available 
studies are limited by small sample size, cross-sectional study design, or focus on perturbed host states like severe 
infection or prematurity. To characterize immune ontogeny among healthy full-term newborns, we assessed 
plasma cytokine and chemokine concentrations across the first week of life in a robust longitudinal cohort of 
healthy, full-term African newborns. 
Methods: We analyzed a subgroup of a cohort of healthy newborns at the Medical Research Council Unit in The 
Gambia (West Africa; N = 608). Peripheral blood plasma was collected from all study participants at birth (day of 
life (DOL) 0) and at one follow-up time point at DOL 1, 3, or 7. Plasma cytokine and chemokine concentrations 
were measured by bead-based cytokine multiplex assay. Unsupervised clustering was used to identify patterns in 
plasma cytokine and chemokine ontogeny during early life. 
Results: We observed an increase across the first week of life in plasma Th1 cytokines such as IFNγ and CXCL10 
and a decrease in Th2 and anti-inflammatory cytokines such as IL-6 and IL-10, and chemokines such as CXCL8. In 
contrast, other cytokines and chemokines (e.g. IL-4 and CCL5, respectively) remained unchanged during the first 
week of life. This robust ontogenetic pattern did not appear to be affected by gestational age or sex. 
Conclusions: Ontogeny is a strong driver of newborn plasma-based levels of cytokines and chemokines throughout 
the first week of life with a rising IFNγ axis suggesting post-natal upregulation of host defense pathways. Our 
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growth factor; IFN, interferon; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; FGF, fibroblast growth 
factor; Treg, Regulatory T cell. 
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study will prove useful to the design and interpretation of future studies aimed at understanding the neonatal 
immune system during health and disease.   
1. Introduction 
The first weeks of life represent a period of great ontogenetic change 
in immunity as well as marked susceptibility to infection [1,2]. Newborn 
vulnerability during the first few weeks of life reflects the development 
of a highly complex immune system [3]. As the neonatal immune system 
adjusts to its new ex utero environment, it faces many challenges, 
requiring better understanding and identification of markers associated 
immune maturation in relation to health and disease. 
Cytokines and chemokines are low-molecular-weight proteins and 
key immune signaling molecules with pleiotropic effects on innate and 
adaptive immune responses [3–5]. Acting via cognate receptors on 
leukocytes and other host cells, the network of cytokines and chemo-
kines is referred to as the ‘cytokine milieu’, because its function and 
effect depend on the target cells in diverse tissues. Cytokines and che-
mokines regulate complex processes such as inflammation, cellular 
proliferation, differentiation, and development by targeting specific 
cells[3]. 
Human plasma contains basal concentrations of a range of cytokines 
and chemokines [6,7]. In adults and older children, plasma cytokine and 
chemokine concentrations are altered by a range of factors such as age 
[9–14], sex, seasonality, and exercise [15–17], yet our understanding of 
early life ontogeny of neonatal plasma cytokine and chemokine con-
centrations is limited. These concentrations can be affected by matura-
tion [16,18 19–23], as well as infectious and/or inflammatory states 
[24–30]. 
Interest in defining cytokines and chemokines in early life is driven 
in part by the distinct vulnerability of the newborn. 44% of under 5-year 
mortality occurs within the neonatal period, with ~75% of all newborn 
deaths occurring in the first week of life [31]. Furthermore, the majority 
of these deaths occur in low- and middle-income countries. Cytokines 
are key players in the pathology of disease and development of thera-
peutics[32], therefore, characterizing immune trajectories of healthy 
full-term infants may provide insight into how the infant immune 
development shapes the susceptibility to disease and responses to 
vaccine. 
Prior studies of plasma cytokine and chemokine concentrations in 
infants and/or children have been limited by small sample size (n < 20) 
[33] as well as confounders such as antibiotic treatment [29,30,34] or 
premature [35–37] participants. Plasma concentrations of IL-1Ra, 
CXCL10, and TNF-α demonstrated a 60% decrease in children, aged 
0.1–12.8 years of age, over time[16]. Given the rapid changes in human 
immunity, to our knowledge, no other study has characterized the lon-
gitudinal trajectory of plasma cytokines and chemokines over the first 
week of human life in a large cohort of healthy, full-term infants. 
The objective of this study was to characterize the normal ontogeny 
of plasma cytokines and chemokine concentrations in a healthy, term 
African infant cohort over the first week of life. Such an effort provides 
insight into normal development and may inform future studies of 
variance from usual plasma cytokine/chemokine trajectories in the 
context of early life disease. Using a standardized, multiplex-based 
assay, we measured a diverse range of cytokine and chemokine pro-
files and utilized time series clustering to define ontogenetic trajectories 
during normal neonatal development. We found that plasma cytokine 
and chemokine concentrations clustered into distinct kinetic groups, 
including a rise in IFNγ-related cytokines across the first week, sug-
gesting a coordinated ontogeny across the first week of human life. 
2. Methods 
2.1. Study design and sample collection 
The clinical protocol for this study EPIC002 has been previously 
described[38,39]. The study is registered on clinicaltrials.gov as 
NCT03246230. In brief, mothers-infant pairs were consented and 
enrolled at time of delivery at the Medical Research Council (MRC) Unit 
at the London School of Hygiene and Tropical Medicine in The Gambia. 
HIV- and Hepatitis B-negative mothers 18 years or older, were enrolled. 
Infants were enrolled if >36 weeks of gestational age (as determined by 
Ballard scoring), with Apgar scores >8 at 5 min and birth weight >2.5 
kg. Peripheral blood samples (max volume 2 ml) were collected from 
infants using sterile sodium heparin tubes (Becton Dickinson). Four time 
points were collected: Visit 1 (V1), was collected within the first 24 h of 
life (Day of Life (DOL)0); while the Visit 2 (V2) sample was collected at 
either DOL1, or DOL3, or DOL7. Plasma samples were processed for 
analysis as previously published [40]. All plasma samples were stored at 
− 80 ◦C until use. Local and International IRB committees approved all 
protocols utilized. 
2.2. Cytokine and chemokine qualification methods 
Reagents: Milliplex Human Cytokine/Chemokine MAGNETIC BEAD 
Premixed 41 Plex Kit. (Millipore cat. #HCYTMAG-60K-PX41), Dulbec-
co’s phosphate-buffered saline (dPBS, cat. #14190), and Corning Cell-
BIND® 384 well plates (cat. #CLS3764). 
Cytokine/Chemokine assay: The Luminex assay was performed 
across 7 Luminex plates. Plasma was diluted 1:2 in dPBS. Cytokines and 
chemokines were measured using the 41-plex Millipore Milliplex Map 
Kit (cat. #HCYTMAG-60K-PX41), which contains; sCD40L, EGF, FGF-2, 
Flt-3 ligand, Fractalkine, G-CSF, GM-CSF, GRO (CXCL1), IFN-α2, IFN-γ, 
IL-1α, IL-1β, IL-1ra, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8 (CXCL8), IL-9, IL- 
10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17A, IP-10 (CXCL10), MCP- 
1 (CCL2), MCP-3 (CCL7), MDC (CCL22), MIP-1α (CCL3), MIP-1β 
(CCL4), PDGF-AB/BB, RANTES (CCL5), TGF-α, TNF-α, TNF-β, VEGF, 
Eotaxin (CCL11), and PDGF-AA. Plasma samples were assayed using a 
384-well plate platform following the manufacturer’s instructions, 
including the provided controls. Samples were analyzed using a Flexmap 
3D system with Luminex xPONENT software (Luminex Corp.; Austin, 
TX, USA). 
The xPONENT software files were processed using the drLumi R 
package. We fitted 4-parameter logistic, 5-parameter logistic, and 
exponential functions to the dilution series data for each analyte using 
the scluminex function implemented in drLumi (drLumi::scluminex()), 
selecting the best fit function in each case. These were then used to 
determine the lower and upper limits of detection and quantification for 
each analyte and plate. Analytes that fell below or above these values 
were imputed to the lower or upper limit of quantification, respectively. 
For a given sample and analyte, if readings were <30 beads, concen-
tration values were discarded. Samples with all analytes below the lower 
limit of detection (LLD) were also excluded from analysis. 
2.3. Statistical analysis 
Cytokine and chemokine values were log transformed. ComBat (R 
package) was used to carry out batch-correction (normalization) across 
plates based on plate-specific bias identified by PCA. A universal refer-
ence standard sample set was added to each plate and used as a bridge 
sample set across plates. 
Cytokines or chemokines with near-zero variance were identified 
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using the nearZeroVar function from the caret R package (low per-
centage of unique values; high ratio of the frequency of the first and 
second most frequent values). Near-zero variance cytokines (IL-2, IL-3, 
and IL-17A) had few values above their respective LLD and were 
excluded. 
Principal component analysis (PCA) was employed to summarize 
variability in the log10-transformed cytokine concentration and fold 
change datasets, using R packages FactoMineR_2.3 and factoextra_1.0.7. 
All cytokines were centered and scaled to unit variance. 
Statistical differences in cytokine levels between DOL were assessed 
using the Wilcoxon signed-rank test. Fold-change values were calculated 
by indexing untransformed concentration values to DOL0, then log10- 
transforming. P-values < 0.05 were considered significant, and the 
Holm-Bonferroni method using n = 38 cytokines was used to adjust for 
multiple comparisons. Associations of cytokines with biological sex, 
ethnicity, maternal age, and gestational age were tested to assess if there 
were any other factors with significant effects on cytokine concentra-
tions. Each cytokine was modeled as a dependent variable in separate 
linear models, with the variable of interest, a Visit term, and an inter-
action term as independent variables. 
To identify groups of cytokine and chemokines with common tra-
jectories across the first week of life, we performed time series clus-
tering. The log10-transformed cytokine concentrations were first 
standardized. Average time series were constructed by taking the mean 
of each cytokine at each DOL. The distances between cytokine time se-
ries were calculated with dynamic time warping, using the R package 
dtw_1.21-3 [41]. This approach yielded improved time series clusters 
compared to the Euclidean distance metric. We then performed 
complete-linkage agglomerative hierarchical clustering on the resulting 
cytokine distances. Five cluster were identified by maximizing the 
average silhouette width between clusters. 
To assess the robustness of our clustering approach, we repeated the 
procedure across 1000 bootstrap re-samplings using 90% of the data 
(random selection of 540 out of the 608 participants), and used the 
frequencies with which cytokines co-clustered to calculate the final 
groupings, as previously described[42]. In addition, we compared our 
clusters to those obtained when carrying out consensus clustering on the 
two time points from each individual, without averaging, to preserve 
individual-level information[43]. Both methodologies were found to 
produced similar cytokine and chemokine clusters. 
3. Results 
3.1. Cohort enrollment and baseline characteristics of study participants 
608 healthy Gambia mother-newborn pairs from the EPIC-002A 
cohort were analyzed in this study. The cohort demographic table 
(Table 1) indicates that the plurality of mothers (29.1%) were 25–29 
years old, followed by age 20–24 years old (22.2%) and then age 30–34 
(20.7%). An approximately equal ratio of male (50.7%) to female 
(49.3%) newborns were enrolled. The average birth weight was 3.16 kg. 
A few (n = 4, 0.7%) preterm newborns (<37 weeks gestation) were 
enrolled within the cohort, but the majority (86.2%) of newborns were 
early term (≥37 to <38 weeks gestation) or full term (≥38 to <40 weeks 
gestation). Breastfeeding was initiated for 88.5% of infants at delivery 
and continued after the first day of life (>98.8%) until four months of 
age for infants in this cohort. 
3.2. Association of cytokine and chemokine concentration and 
demographic factors 
Initially, we investigated the associations between plasma cytokine 
and chemokine concentrations and physical findings at birth, as these 
can be early indicators of post-natal conditions (i.e., early onset sepsis). 
There were no significant differences observed in plasma concentrations 
cytokines and chemokines in relation to respiratory rate, heart rate, 
weight, length, head circumference, or temperature at birth (data not 
shown). 
We also examined the correlation between plasma cytokine and 
chemokine concentrations and demographic clinical data over the first 
week of life. No significant correlations were observed between de-
mographic parameters such as sex, maternal age, gestational age or 
breastfeeding with cytokines and chemokines measured at DOL 1, 3, or 
7. 
3.3. Ontogenetic changes across the first week of life 
To identify potential ontogenetic changes, we measured the con-
centration of the plasma cytokines and chemokines in 608 healthy 
Gambia mother-newborn pairs (n = 202 at DOL1, n = 206 at DOL3, n =
200 at DOL7) over the first week of life. Principal component analysis 
(PCA) demonstrated the expression of cytokines and chemokines. The 
first two principal components (PC1 and PC2) accounted for 35.4% of 
total variance (Fig. 1A). PC2 captures the differences between Visit 1 
and Visit 2, accounts for ~10% of total variance. PC3 also contained 
some variance information from ontogenetic changes between Visit 1 
and Visit 2 (Supp Fig. 1A; ~6.6% of total variance). The PCA loadings 
illustrate that TGFα, CXCL8, sCD40L, CCL4, IL-6, and PDGF-AB/BB are 
elevated at birth (Visit 1) relative to Visit 2 (DOL 1, 3, or 7). Fig. 1B lists 
the top 15 contributing cytokines and chemokines, while Supp Fig. 1B 
demonstrates all cytokines and chemokines. 
3.4. Increase of plasma cytokine and chemokine ontogeny changes with 
the increase of age 
We tested whether the relative abundances of individual cytokines 
and chemokines changed across the first week of life (Fig. 1C; Supple-
mentary Table 1). At DOL1, plasma concentrations of CXCL10, IFNγ, 
CCl2, and IL-5 were all significantly higher over DOL0, while EGF, 
sCD40L, G-CSF, and IL-6 are significantly lower. DOL3 revealed more 
pronounced differences from DOL0, with greater increases in CXCL10, 
IFNγ, IL-5, and IL-1α, and a downregulation of CXCL8, TGFα, IL-6, IL-10, 
PDGF-AB/AA, and G-CSF. Lastly, at DOL7, IFNγ, CXCL10, and IL-5 
Table 1 
Demographic characteristics of the study participants.  
Characteristics Frequency (n) Percent (%) 
Sex of Baby: 
Female/Male 300/308 49.3/50.7  
Birth weight (kg): 
Avg (±SEM) 3.16 ± 0.015   
Age of mothers (years): 
18–19 years 26 4.3 
20–24 years 135 22.2 
25–29 years 177 29.1 
30–34 years 126 20.7 
35–39 years 109 17.9 
40–45 years 35 5.8  
Term of Baby: 
Preterm (<37 weeks) 4 0.7 
Early term (37–38 weeks) 150 24.7 
Full term (39–40 weeks) 374 61.5 
Late term (>40 weeks) 80 13.2  
Ethnicity of Baby: 
Mandinka 291 47.9 
Jola 96 15.8 
Fula 79 13.0 
Wollof 68 11.2 
Serahule 22 3.6 
Others 52 8.6  
Frequency of breastfeeding: 
Visit 1 (Yes/No) 538/70 88.5/11.5 
Visit 2 (Yes/No) 601/7 98.8/1.2  
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continue to be significantly upregulated, while CXCL8, TGFα, IL-6, 
CCL4, IL-10, IL-1RA, and G-CSF, were significantly downregulated. 
3.5. Plasma cytokine and chemokine cluster by time series analysis during 
the first week of life 
Time series clustering highlighted specific patterns of plasma cyto-
kine and chemokine concentrations over the first week of life (Fig. 2). 
Hierarchical clustering of mean standardized, dynamic time warped 
cytokine and chemokine profiles across the first week of life revealed 
five clusters of cytokines (Fig. 2B, Supp Fig. 2). The trajectories of these 
clusters are shown in Fig. 2B, along with the mean trajectories of their 
component cytokines and chemokines. Error bars represent 95% confi-
dence intervals for the cluster mean (Supp Table 1). Paired t-tests were 
performed to test whether the cluster concentrations were significantly 
different between DOL0 and subsequent days of life (Supp Fig. 2). 
As a sensitivity analysis, we compared our cluster method to an in-
dependent validation method[43]. We compared the consensus values 
of both methods, which can be interpreted as the frequency that cyto-
kines are placed into the same cluster across repeated runs[43]. The 
average consensus for clusters 1–5 was 79.4% using the main method-
ology and 53.9% using the validation methodology. 
Representative cytokines and chemokines for each cluster are shown 
in Fig. 2C to illustrate the variation within groups. Paired t-tests of 
cytokine concentrations between DOL0 and the follow-up visits were 
employed to assess for significance. The detailed pattern of each cyto-
kine and chemokine was analysed as standardized log10- as well as raw- 
concentrations and depicted in Supplementary Fig. 2A and 2B, respec-
tively. This analysis suggested that there are distinct trajectories for 
different groups of cytokines and chemokines during the first week of 
life. 
4. Discussion 
In this study, plasma cytokines and chemokines were measured in a 
longitudinal cohort of healthy, full-term Gambian newborns throughout 
the first week of life, using highly standardized, quantitative multiplex 
protein assays. A variety of longitudinal changes were observed. Plasma 
concentrations of CXCL10, GM-CSF, IFNγ, and IL-5 increased over the 
first week of life while those of CCL4, CXCL8, G-CSF, IL-10, IL-1RA, IL-6, 
and TGFα decreased. We thus observed that ontogeny is a strong driver 
of human neonatal plasma cytokine and chemokine concentrations. 
Cytokines and chemokines are key signaling proteins that act via 
cognate receptors to shape immune responses [6]. In early life, cytokines 
and chemokines play a crucial role in the maturation and development 
of lymphoid progenitors [44]. Our findings indicate a significant in-
crease of Th1 cytokines and a significant decrease of pro-inflammatory 
and regulatory cytokines and chemokines across the first week of life. 
We observed a significant increase of Th1-polarizing cytokines, 
including IFNγ, IFNγ-inducible CXCL10 (IP10), GM-CSF, which may 
contribute to progressive development of cell mediated immunity with 
age, as well as IL-5, a Th2-polarizing cytokine that contributes to 
eosinophil activation. Plasma IFNγ concentrations rose significantly 
though modestly across the first week of life, along with those of IL-12 
and TNFα, consistent with the generally tight regulation of cytokines 
and limited ability of human neonatal leukocytes to produce these cy-
tokines [33,45,46]. Of note, IFNγ is important to early life host defense 
[47] as: 1) low birthweight newborns who are highly susceptible to 
Fig. 1. Ontogeny of plasma cytokines and 
chemokines over the first week of life. A. 
Principal component analysis (PCA) demon-
strating ontogeny of plasma cytokine and che-
mokines. PCA was used to plot log10-transformed 
plasma cytokine/chemokine concentrations and 
revealed sample clustering by Visit (age) in EPIC- 
HIPC Gambia cohort. B. Cytokine loadings on 
principal components 1 and 2. C. Volcano plots 
provide further resolution of the ontogeny of 
cytokine and chemokines. Volcano plots with 
cytokine/chemokines significantly increased over 
day of life (DOL) 0 in EPIC-HIPC Gambia cohort 
across the first week of life. Significant cytokines 
or chemokines (p-value < 0.01, absolute log2 
[fold change vs DOL0] > 0.2) are marked in red 
with abbreviated cytokine/chemokine names. A 
paired Wilcoxon was used to test for cytokine 
significance. (n = 608 participants for Visit 1 and 
Visit 2: 202 DOL1, 206 DOL3, 200 DOL7).   
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infection are relatively deficient in IFNγ production[48]; 2) Addition of 
IFN-γ to human newborn blood in vitro enhanced innate immune func-
tion including leukocyte responses to bacteria and plasma opsonopha-
gocytic activity; and 3) IFNγR deficient children present in early life 
with severe mycobacterial infections[49]. Thus the rise of IFN and IFN- 
associated CXCL10 can be viewed as a gradual ontogenetic enhancement 
in the ability to confront intracellular pathogens. 
Newborns emerge out of a highly regulated maternofetal environ-
ment aimed at protecting non-self (the fetus) from self, the maternal 
immune system, while in utero. For example, the placenta produces 
mediators such as progesterone and prostaglandin to promote a Th2 bias 
in the fetus [50,51]. Human neonatal antigen-presenting cells demon-
strate reduced stimulus-induced production of Th1- and Th17 -type 
cytokines coupled with preserved production of Th2 -type cytokines, 
contributing to an anti-inflammatory environment in utero that reduces 
the risk of abortion or pre-term delivery[46]. 
Although the in utero environment is highly tolerogenic, due to a 
variety of immunosuppressive mechanisms [52–54], birth itself is a 
controlled inflammatory process. Collaboration between innate and 
adaptive immune responses is required to sustain pregnancy [55], and 
disturbance of this balance occurs during physiological labor. In contrast 
to the Th1-type cytokine increase, we found a significant decrease of 
CCL4, CXCL8, IL-6, IL-1RA, G-CSF, IL-10, and TGFα over the first week 
of life. A decline in pro-inflammatory and pro-resolution cytokines and 
chemokines including CXCL8, CCL4, and IL-6 [56], along with anti- 
inflammatory factors including IL-10 and TGFα, might reflect resolu-
tion of the birthing process. 
After birth, the immune system begins to transition towards a 
complex and microbe-rich extra-uterine environment. The establish-
ment of the gut microbiome begins at birth[57] and continues to 
develop until ~3 years of age [58–60, and maintains interplay with the 
developing immune system[61]. The increase in plasma concentrations 
of IFNα2, IL-12p70, IL-13, IL-1a, IL-9, and TNFα support an ontogeny- 
based transition away from the highly regulated maternofetal environ-
ment towards the more diverse ex utero environment. A previous study 
looking at 24 matched samples, found no difference between maternal 
blood and newborn cord blood from elective Cesarean deliveries with 
respect to plasma concentrations of IL-6, CXCL-8, IL-10, and IL1-RA 
(PMID 26136749). Our study, focused on vaginal deliveries, was not 
designed to correlate maternal cytokine levels with that of the neonates, 
though based on the aforementioned study we hypothesize that cytokine 
concentrations at birth likely correlate with those in maternal plasma. 
Of note, plasma concentrations of certain cytokines such as IL-6 are 
higher in vaginal vs. C-section delivery[29]. 
We did not observe any significant differences in cytokine concen-
trations between infants who were breastfed vs those who were formula 
feed (data not shown). Despite this observation, it remains possible that 
breast milk cytokine concentrations may impact those of in infant 
plasma[62,63], as: 1) analysis of plasma cytokines and chemokine 
concentrations beyond the first week of life may demonstrate differences 
between breastfed and non-breastfed levels; 2) detecting potential dif-
ferences in plasma cytokines due to breastfeeding may require specific 
focus on mucosal immunity/oral tolerance, as has been reviewed[64], 
and correlations with maternal plasma cytokine/chemokine concentra-
tions as well as maternal breastmilk cytokine/chemokine concentrations 
that differ by parity status[62]. Overall, there is need for additional 
Fig. 2. Time series analysis across the first week of life demonstrates distinct cytokine/chemokine cluster patterns. A. Time series clustering. Hierarchical 
clustering was performed to group cytokines and chemokines based on their mean time series. B. Cytokine traces by cluster. The mean cluster (solid line) and 
cytokine (dashed line) traces for each day of life (DOL) show consistent trajectories within each cluster across the first week of life. Error bars represent 95% 
confidence intervals for the cluster mean. The cytokines in clusters 1 and 2 exhibit small changes over the first week of life, with some reaching transient troughs or 
peaks at DOLs 1 and 3. The cytokines in cluster 3 rise slowly across the first week of life. Cluster 4, which primarily contains inflammation-associated cytokines such 
as IL-6 and IL-10, shows a steady decrease across the first week of life. The cytokines in cluster 5, including IFNγ and CXCL10, increase rapidly between birth and 
DOL1, then peak and reverse course by DOL3. C. Representative cytokines were chosen for each cluster to show the variation within groups. Statistical comparison 
employed T-tests on standardized cytokine concentrations for paired samples between DOL0 and the follow-up visit. (****: p < 0.0001, ***: p < 0.001, **: p < 0.01, 
*: p < 0.05. n = 608: 202 DOL1, 206 DOL3, 200 DOL7.) 
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studies on the relation of method of delivery[29], breast- vs formula- 
feeding, and early life immune ontogeny. 
Consistent with other studies of cytokines and chemokines in early 
life [34,65], we did not observe sex-related differences in plasma cyto-
kine and chemokine concentrations. Previous studies in healthy children 
>1 month old have found age- and sex- differences in plasma cytokines 
and chemokines, potentially due to sex hormones [16,18,23,66]. Given 
that there are age-dependent sex differences later in life [67,68], future 
studies should investigate at which timepoint these sex-dependent 
cytokine changes occur and whether any such changes correspond to 
sex-specific differences in innate and adaptive immunity. 
Given growing evidence of rapid changes in infant immunity [40], 
our study was designed to capture clinical and cytokine/chemokine data 
from the day of birth. Cytokines and chemokines in Cluster 1 (CCL3, 
CX3CL1, CXCL1, EGF, IL-12p40, PDGF-AB/BB, sCD40L, VEGF) and 
Cluster 2 (CCL2, CCL5, CCL7, Eotaxin, IL-15, IL-4, IL-7, PDGF-AA, TNFβ) 
play a crucial role in activating or mediating the host immune response 
to pathogens. These changes over the first week of life illustrate the 
dynamic nature of the early life immune system. Several reviews detail 
the function of each of these cytokines and chemokines [16,18,19–23]. 
Our results have potential translational applications. Compared to 
adults, infants have increased susceptibility to infection, yet most pre-
ventative strategies for neonates rely upon our understanding of the 
adult immune system. Inflammatory protein markers such as those 
regulated by IL-6, like C-reactive protein (CRP), are important clinical 
analytes for early onset neonatal sepsis [69,70]. In infants, G-CSF, IL-6, 
CXCL8 (IL-8), and TNF-α have been identified as potential markers of 
Gram-negative bacteremia in the neonatal intensive care unit [71]. 
There remains an unmet need to define effective biomarkers of early 
onset sepsis, defined as less than 72 h in pre-term infants, and less than 7 
days in term infants [69,72]. 
The age-dependent changes observed here suggest that plasma cy-
tokines and chemokines have day of life-specific normal ranges, with 
future studies needed to further validate this finding. We observed a 
clear plasma cytokine/chemokine ontogeny signature during the first 
week of life. As cytokines, such as IFN-γ and IL-1β, can contribute to 
“innate memory” or trained immunity [73 74 75], future studies should 
investigate the relationship of these plasma cytokines, both at baseline 
and after infection or immunization, on measures of trained immunity. 
Indeed, characterizing immune trajectories in healthy newborns will 
help address questions concerning how distinct early life immunity 
shapes susceptibility to disease. 
Our study also has a number of limitations. Although the number of 
infants included in this study is substantial, samples were collected at a 
single study site in The Gambia (West Africa), requiring further studies 
to assess the generalizability of these findings. Nevertheless, our 
observation of significant changes in the cytokine IFNγ and related 
chemokine, the IFNγ-inducible CXCL10, with similar trajectories noted 
in geographically and genetically distinct newborns in Papua New 
Guinea [39] suggests that the patterns we observed have broader 
applicability. Secondly, we do not yet know whether the observed tra-
jectories remain consistent between the first week of life and the 
remainder of the vulnerable neonatal period, defined as first 28 days of 
life. This is a key question in the field of immune ontogeny and will 
require further study. 
5. Conclusion 
Our findings demonstrate an age-dependent pattern of plasma cy-
tokines and chemokines in healthy, term Gambian infants, representing 
an ontogenetic trajectory reflective of the initiation of a post-birth 
transition from a Th2-polarized to a more balanced Th1/Th2 immune 
state. Our findings help define the baseline trajectories of plasma cyto-
kines and chemokines in healthy newborns and will inform future 
studies to correlate plasma cytokines and chemokines with responses to 
immune challenge such as immunization, as well as deviations from 
healthy trajectories due to infection or other diseases. 
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[65] J. Chávez-Alderete, L. Gochicoa-Rangel, R. Del-Río-Hidalgo, S. Guerrero-Zúñiga, 
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